The multi-million-dollar collaboration between Novo Nordisk and US-based Dicerna, dealing with the development of new potential RNA drugs, has seen its second candidate, the former tells MedWatch.
According to the pharmaceutical companies, the selection occured in the first half of the year, meaning that so far, the partnership, which was announced in 2019, has resulted in two preclinical candidates for futher developement. Both are within cardiometabolic diseases, which is all Novo Nordisk is prepared to say.
Already a subscriber? Log in.
Read the whole article
Get 14 days free access.
No credit card required.
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers.Start a free company trial today
Your trial for MedWatch has now started
With your free trial you get:
Full access to all locked articles on MedWatch.
Daily newsletter and ongoing top-newsletters. You can unsubscribe and subscribe to our newsletters anytime.
When your trial period expires
You will not be transferred to a paid subscription.
You will continue to receive our newsletters after the trial period expires. You can unsubscribe at the bottom of each newsletter.
More from MedWatch
In the largest study ever of its kind, patient data from the "real world" documents the long-term effects of up to nine years of ALK vaccines. Up until now, it has not been possible to demonstrate these in ordinary clinical studies where the follow-up period is shorter, and the new knowledge could be a turning point in ALK's dialog about prices and subsidies with authorities and payers.